Volume 98, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Pyronaridine, a Mannich base antimalarial agent with a high activity against chloroquine-resistant , has been combined with artesunate as a new artemisinin based combination therapy (ACT). Pyronaridine–artesunate combination could be one of the choices for the treatment of uncomplicated falciparum malaria in multidrug-resistant areas including Thailand. The aim of this study was to determine in vitro sensitivity and cross-resistance pattern of pyronaridine in Thai isolates of . In addition, the influence of resistant genes concerning in vitro pyronaridine sensitivity was determined. The mean pyronaridine 50% inhibitory concentration (IC) of 118 parasite isolates was 5.6 ± 3.1 nM (range = 0.2–15.4 nM) with a significant positive correlation with artesunate IC ( = 0.246, = 0.008) and amodiaquine IC ( = 0.220, = 0.042) and a significant negative correlation with quinine IC ( = 0.185, = 0.047). Parasites containing the 86Y allele exhibited significantly reduced pyronaridine sensitivity compared with those with the N86 allele (7.6 ± 3.3 nM and 5.4 ± 3.0 nM, respectively, = 0.032, independent test); however, the difference may not be clinically relevant. Pyronaridine–artesunate could be the candidate ACT to treat multidrug-resistant falciparum malaria in Thailand with careful monitoring.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...


Data & Media loading...

  • Received : 06 Apr 2017
  • Accepted : 23 Aug 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error